Pulling SEC filings + quote and writing the call…

Aimei Health Technology Co., Ltd.
Next earnings Aug 11, 2026
Pre-deal blank-check SPAC with negative equity trading ~$27 on a binary, repeatedly-delayed China-approval merger — speculation, not investment.
Net income (FY2025) $1.06M · FY2025
AFJK is not an operating business — it is a Cayman Islands blank-check (SPAC) shell whose entire FY2025 net income of $1.06M came from interest on cash in the Trust Account ($1,895,527 of trust interest less $835,759 of G&A), with the filing stating plainly: 'We have neither engaged in any operations nor generated any revenue to date.' Operating income is negative (-$836K) and operating cash flow is negative (-$565K). There is no revenue line, no margin, no franchise — the standard fundamentals lens does not apply. What matters is the trust, the deal, and the price relative to redemption value.
The balance sheet is hollowed out and stressed. Total assets collapsed 83.6% YoY to $12.1M (the signature of heavy shareholder redemptions, consistent with shares outstanding falling 48.3% to just 3.17M), while total liabilities jumped 169.5% to $4.06M and current liabilities surged 312.7% to $3.37M against essentially no current assets ($2.93K). Stockholders' equity is negative (-$4.06M), a liabilities/equity of -1.00x. The entire equity question hinges on one binary event: the proposed business combination with United Hydrogen.
| Line item | FY24 | FY25 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$1.06M | -$836K |
| Net income | $2.55M | $1.06M |
| Diluted EPS | — | — |
| Net margin | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Officer/director change (Item 5.02), likely tied to pending United Hydrogen close
Q1'26: pre-deal SPAC, interest income only; merger still awaiting CSRC approval
Incurred new financial obligation—likely sponsor extension loan into trust
Received Nasdaq continued-listing deficiency notice (Item 3.01); delisting risk
New financial obligation incurred, likely sponsor extension funding for trust
FY25 net income $1.06M (-59%); trust depleted by redemptions; close eyed May'26
Received Nasdaq listing-deficiency notice (Item 3.01); delisting risk
Incurred new financial obligation, likely sponsor loan to fund trust extension
Notified SEC the FY25 10-K would be filed late (Form NT 10-K)
Sources: SEC EDGAR (CIK 0001979005, latest 10-Q filed 2026-06-16) · analysis by claude-code · as of 6/30/2026, 12:25:25 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
| 2025-02-11 | MIZUHO SECURITIES USA LLC 10% owner | Sell | 150K @ $10.86 | $1.63M |
| 2023-12-01 | Aimei Investment Ltd 10% owner | Buy | 332K @ $10.00 | $3.32M |
1192 tracked peers · median